Parkev Tatevosian, CFAPublished 2026-09-26
“Novo Nordisk Gives Uninspiring Outlook”
$NVOBullish
NVO is a buy despite lowered valuation and conviction; significant upside remains.
Novo Nordisk informed investors that it will increase its revenue at a medium single-digit rate through 2030. It also stated that it will increase the number of patients it serves to more than 60 million, up from about 46.5 million currently.
Despite these strong expectations, investors were not impressed with Novo Nordisk's performance. The stock has fallen by more than 25% since the beginning of 2026. So, does all this make Novo a buying opportunity when its price drops?